Invention Grant
- Patent Title: Compound that specifically binds to KIR3DL2 for use in the treatment of peripheral T cell lymphoma
-
Application No.: US15623572Application Date: 2017-06-15
-
Publication No.: US10174112B2Publication Date: 2019-01-08
- Inventor: Cecile Bonnafous , Helene Sicard , Renaud Buffet
- Applicant: INNATE PHARMA
- Applicant Address: FR Marseilles
- Assignee: INNATE PHARMA
- Current Assignee: INNATE PHARMA
- Current Assignee Address: FR Marseilles
- Agency: Saliwanchik, Lloyd & Eisenschenk
- Main IPC: A61K39/00
- IPC: A61K39/00 ; A61K39/395 ; C07K16/28 ; C07K16/30 ; G01N33/574
Abstract:
The present invention relates to methods for the treatment, prevention and diagnosis of peripheral T cell lymphoma using compounds that specifically bind KIR3DL2. The invention also relates to use of antibodies that specifically bind KIR3DL2 in diagnostic and theranostic assays in the detection and treatment of peripheral T cell lymphoma.
Public/Granted literature
- US20170298132A1 COMPOUND THAT SPECIFICALLY BINDS TO KIR3DL2 FOR USE IN THE TREATMENT OF PERIPHERAL T CELL LYMPHOMA Public/Granted day:2017-10-19
Information query
